Since the Organon spinoff, the strategy to focus on specific parts of the portfolio is clearer than ever. We are fully committed to working on three…
In Conversation
... price erosion is such a big concern in the Spanish market ... The pricing system for generics is forcing both brands and generics to compete…
We are one of the few companies focusing heavily on pain. There are not many ... because is not an easy area in which to bring…
... the difference between IBSA and other companies is that we have both pharma and medical devices ... We develop and patent new technologies to deliver…
... the decision to combine our capabilities in the US allowed Stevanato Group to reach an agreement with the Biomedical Advanced Research and Development Authority (BARDA)…
... the needs of our customers go way beyond catheters, stents or artificial pacemakers; we try to go alongside them through their particular journey with patients.
... these different therapeutic platforms are based upon how we can handle these T-cells to attack cancer, and then how we can manage, modify or improve…
Our mission is focused on providing support to the pharmaceutical and biomedical industries from the beginning of a project to its completion, in reducing the timeline…
[In Italy] we have the full pharma and life science value chain from the early start of research to the manufacturing and selling of drugs ...…
The pandemic encouraged people to focus more on their health in one way or another. This creates the opportunity for a bigger focus on preventative care.…
The pandemic revealed the importance of having assets like our plant within the European territory. The most important thing for Reig Jofre is ... the fact…
Aristo differentiates itself in the market through its dynamism and its ability to move quickly and diversify its business ... the company will soon move into…
